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Background: Mild hypothermia may be frequently induced due to cool environments in the operating room. The
study analyzed patient recovery time and response to sugammadex after a prolonged rocuronium-induced deep
neuromuscular block (NMB) during mild hypothermia.
Methods: Sixty patients were randomly (1:1) allocated to the mild hypothermia and normothermia groups, defined as
having core temperatures between 34.5 - 35°C and 36.5 - 37°C, respectively. Patients received 0.6 mg/kg of rocuronium,
followed by 7 – 10 μg/kg/min to maintain a deep NMB [post-tetanic count (PTC) 1–2]. After surgery, the deep NMB was
reversed with sugammadex 4.0 mg/kg. The primary end-point was the time until the train-of-four (TOF) ratio was 0.9.
Results: The appropriate neuromuscular function (TOF ratio≥ 0.9) was restored after sugammadex was administered,
even after hypothermia. The length of recovery in the hypothermia patients [mean (SD), 171.1 (62.1) seconds (s)] was
significantly slower compared with the normothermia patients [124.9 (59.2) s] (p = 0.005). There were no adverse effects
from sugammadex.
Conclusions: Sugammadex safely and securely reversed deep rocuronium-induced NMB during mild hypothermia. An
additional 46 s was required for recovery from a deep NMB in hypothermia patients. Based on the results, we think this
prolonged recovery time is clinically acceptable.
Trial registration: ClinicalTrials.gov Identifier: NCT01965067.
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Inadvertent perioperative hypothermia (<36°C) develops
rapidly in the hour immediately after induction of
general anesthesia, when exposed to a typical cool
operating room environment [1]. Core temperature can be
reduced by 1.6 degrees Celsius (°C) within the first hour
and by 2.8°C during 3 hours in a 22°C air-conditioned
environment [2]. Perioperative hypothermia has been
associated with adverse patient outcomes, the most
significant of which is an increased rate of myocardial
ischemia, coagulopathies, postoperative shivering and
wound infection [3-5]. The duration of vecuronium
blockade is prolonged for twice the amount of time* Correspondence: kimks@hanyang.ac.kr
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unless otherwise stated.when the core temperature is decreased to 34.5°C [6].
So it is important to confirm the effect of core
temperature to the reversal of rocuronium-induced
neuromuscular block.
Sugammadex, a modified γ-cyclodextrin that encapsulates
steroidal neuromuscular block (NMB) agents (such as
rocuronium and vecuronium) in a highly selective fashion,
has been shown to be reliable and complete, and can
rapidly reverse moderate or deep NMB [7]. A deep NMB
state [post-tetanic count (PTC) 1–2] was maintained
until the closure or removal of the last device during
laparoscopic surgery, and which can improve surgical
conditions compared with moderate NMB [8]. The
rapid and reliable antagonistic action of competitive NMB
agents after surgery can enhance the safety and efficacy of
the patients [9]. However, the reversal effect of sugammadex
has not been investigated in mild hypothermia.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the reversibility of deep rocuronium-induced NMB for
the PTC 1–2 steady block with sugammadex during mild
hypothermia with core temperatures between 34.5°C and
35°C or normal thermal conditions.Methods
Study subjects and study design
This randomized, parallel-group, safety-assessor-blinded
phase IV study was approved from the Hospital Ethics
Committee (IRB File No.: HYUH 2013-08-029-005),
was conducted in accordance with principles of Good
Clinical Research Practice, and written informed consent
was obtained from the patients. The current study was
registered at clinical trials.gov under the identification
number NCT01965067 (Merck protocol no. MK8616-099).
Sixty patients of both sexes, ASA physical status I - II,
aged between 21–64 years, that were undergoing elective
abdominal surgery under general anesthesia were
randomly assigned to either the hypothermia group
(n = 30) (mild hypothermia with core temperatures
between 34.5°C and 35°C) or the control group (n = 30)
(normal thermal condition with core temperatures
between 36.5°C and 37°C) using a computer-generated
program. Patients were excluded if they were expected to
have a difficult airway, suffered from neuromuscular,
hepatic or renal diseases and undertaken the surgery on
cardiopulmonary bypass; patients that were using any
medication that might interact with muscle relaxants were
also excluded in addition to pregnant women, and patients
whose body mass index was < 18.5 kg/m2 or > 25 kg/m2.Study procedures
The patients were monitored with electrocardiography,
non-invasive arterial pressure measurement, and pulse
oximetry. Hypnotic depth was evaluated using a bispectral
index (BIS) XP monitor (Model A 2000, Aspect Medical
Systems, Newton, MA, USA). Anesthesia was started using
propofol 2 – 2.5 mg/kg and remifentanil 0.5 μg.kg−1.min−1,
and maintained with sevoflurane 1.1 – 1.6% end-tidal and
remifentanil 0.1 – 0.3 μg.kg−1.min−1 to maintain a BIS
monitor between 40 and 50 throughout surgery. Core body
temperature was continuously observed by a thermocouple
placed in the distal esophagus (DeRoyal®, DeRoyal Industries
Inc., Powell, TN, USA). Core temperature was manipulated
in core temperature ranges: 36.5°C and 37°C in the control
group using forced-air warming (Bair Hugger Model 505,
Arizant Healthcare, Eden Prairie, MN, USA), and 34.5°C
and 35°C in the hypothermia group in a 22°C environment
by surface cooling and the air conditioner fan. The skin
temperature of the monitored arm was maintained at
greater than 32°C with fixed temperature sensor at the distal
end of the forearm in both groups.Neuromuscular monitoring was performed with accelero-
myography using the TOF-Watch SX® (Merck Sharp &
Dohme Corp., Glostrup, Denmark) at the adductor pollicis.
Two pediatric electrodes (CleartrodeTM, ConMed®, Utica,
NY, USA) were placed over the ulnar nerve near the wrist.
A 5-s 50-Hz tetanic stimulus was applied using the
automated CAL2 mode to calibrate the TOF-Watch
SX®, and then a supramaximal current was obtained
after the initial single twitch calibration [10]. A bolus dose
of rocuronium 0.6 mg/kg was injected and tracheal
intubation was performed after a maximum NMB was
achieved. Intermittent positive pressure ventilation
was adjusted to maintain end-tidal carbon dioxide
level between 30 and 35 mmHg. The ulnar nerve at
the wrist was stimulated supramaximally with a TOF
mode every 15 seconds (s). The PTC stimulation was
initially performed 10 minutes (min) after obtaining
complete NMB, and repeated manually every 6 min
to monitor deep NMB throughout the study [11].
Rocuronium (7 – 10 μg.kg−1.min−1) was continuously
infused to adjust to PTC 1 – 2 from 30 min after the
initial dose of rocuronium [12]. After the surgical dressing,
PTC 1 – 2 was confirmed on the TOF-Watch SX® reading,
and then sugammadex 4 mg/kg was injected.
The primary objective was to evaluate recovery
time and response to sugammadex after a prolonged
rocuronium-induced deep NMB during mild hypothermia
between 34.5°C and 35°C. Full recovery from the NMB
was conducted during the administration of sevoflurane
and remifentanil. The time to recovery of a train-of-four
(TOF) ratio of 0.9 was evaluated and normalized by the
baseline TOF ratio to improve the accuracy of NMB data
[13]. Blood pressure, heart rate and BIS were measured at
pre-reversal, post-reversal, recovery and post-anesthetic
visits. The incidence of residual neuromuscular blockade,
post-operative nausea and vomiting (PONV) and adverse
events during mild hypothermia and the normal
thermal condition were estimated for up to 7 days
after administration of sugammadex by the assessor
blinded to the study groups. Extubation was carried
out after consciousness and regular respiration were
confirmed. All neuromuscular results were stored in
the computer and monitored until the end of the study.
Risk factors for PONV were also assessed at baseline and
used to assess the likelihood that any occurrences of
PONV were associated with study therapy [14].
Statistical analysis
For calculations, we used the statistical software package
SPSS version 17.0 (SPSS Inc, Chicago, IL, USA). The
sample size was calculated from the previous results of
the averaged recovery time [mean (SD): 102 (42) seconds
(s)] from deep rocuronium-induced NMB to a TOF ratio
of 0.9 after sugammadex 4 mg/kg [15]. We considered
Figure 1 Flow diagram of study participants in each group.
Table 1 Patient characteristics, duration of anesthesia,






Male/Female (n) 13/17 13 / 17 1
Age, years, mean (range) 48 (26 – 64) 47 (21 – 61) 0.936
Weight, kg, mean (SD) 59.7 (10.1) 59.9 (7.0) 0.906
Height, cm, mean (SD) 162.6 (8.0) 163.2 (7.2) 0.788
ASA I/II (n) 19/11 21/9 0.622
Anesthetic time, hour, mean (SD) 3.1 (1.2) 2.7 (1.1) 0.221
BIS, mean (SD) 46.6 (9.5) 50.8 (8.0) 0.066
Sevoflurane, end-tidal volume %,
mean (SD)
1.34 (0.1) 1.33 (0.1) 0.688
Rocuronium, mg, mean (SD) 113.2 (31.1) 115.8 (40.7) 0.787
Core temperature, °C, mean (SD) 34.8 (0.1) 36.7 (0.1) < 0.001
ASA: American Society of Anesthesiologists; BIS: bispectral index;
SD: standard deviation.
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156 s (SD 66), to be clinically significant in patients during
mild hypothermia. A sample size of 26 patients per group
were needed for a power of 80% at a significance level of
5% (two-sided). We enrolled 30 patients per group to
account for a 10% discontinuation rate. The results were
presented as the mean values (SD or range). Categorical
data was compared between groups using chi-squared
analysis. Between-group comparisons were made using
unpaired t-tests. A repeated measures ANOVA was used
for the changes of blood pressure and heart rate. A p-value
less than 0.05 was considered statistically significant.
Results
Flow diagram of study participants in each group is
shown in Figure 1. Sixty patients were enrolled in this
study, and neuromuscular monitoring was successfully
conducted. The two groups were similar in their
demographic profile, anesthetic time, BIS, end-tidal
concentration of sevoflurane, total dose of rocuronium,
type of surgery, location of abdominal surgery, and core
temperature (Table 1). The target core temperature in
either hypothermia patients [34.8 (0.1)°C] or normothermia
patients [36.7 (0.1)°C] was well maintained at the injection
of sugammadex. In our study, the core temperature was
steadily dropped during the course of the surgery in the
hypothermia patients, and no rapid changes were observed.
The mean recovery time to TOF ratio of 0.9 after
sugammadex 4.0 mg/kg was 171.1 (62.1) s in the
hypothermia group compared with 124.9 (59.2) s in
the normothermia group (p = 0.005) (Table 2). For
most patients (83%; 25/30 patients) in the normothermia
group, the recovery time to the TOF ratio of 0.9 was less
than 180 s. By comparison, in the hypothermia group,
60% of patients (18/30 patients) had recovered to a TOF
ratio of 0.9 within 180 s.
The mean arterial pressure during the 180 s period
following administration of sugammadex was not changed,but the heart rate during the same period decreased
significantly after sugammadex was administered in
both groups (p < 0.001) (Figure 2). Shivering was observed
in four patients in the hypothermia group, which could
be easily controlled by adjusting and administering
meperidine 25 mg intravenously. PONV and any other
adverse effects following administration of sugammadex
were not reported in either group.
Discussion
Our study confirmed that the recovery time to the TOF
ratio of 0.9 after sugammadex administration in deep NMB
was prolonged by 46 s during mild hypothermia (171.1 s)
compared with the normal thermal condition (124.9 s).
Recovery at doses of sugammadex 4 mg/kg in a deep
block at PTC 1–2 occurred within 120 s in younger
adults [16]. Similar recovery time (162 s) after sugammadex
at PTC 1–2 was reported [17]. Our study also demonstrated
that 4 mg/kg sugammadex reversed patients in the control
Table 2 Time from administration of sugammadex to recovery of TOF ratio to 0.7, 0.8, and 0.9
Hypothermia (n = 30) Control (n = 30) p
Time to TOF ratio 0.7, seconds, mean (SD) (range) 110.4 (44.6) (31–200) 81.9 (37.8) (29–163) 0.01
Time to TOF ratio 0.8, seconds, mean (SD) (range) 129.6 (49.8) (46–230) 93.9 (45.3) (29–193) 0.005
Time to TOF ratio 0.9, seconds, mean (SD) (range) 171.1 (62.1) (61–305) 124.9 (59.2) (46–298) 0.005
TOF: train-of-four; SD: standard deviation.
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(59.2) s. However, sugammadex reversed the state within
171.1 (62.1) s from a rocuronium-induced deep NMB
in hypothermia patients. The mechanism by which
hypothermia prolongs the reversal from deep NMB
with sugammadex remains controversial. The duration
of action and rocuronium recovery were prolonged by
moderate hypothermia (nasopharyngeal temperature:
30.4°C) due to reduced plasma clearance [18]. The
adequate reversal of vecuronium block by neostigmine
can be delayed during hypothermia (34.5°C) (more than
30 min) due to the prolonged duration of vecuronium and
a decreased efficacy of neostigmine [6]. However, we found
that, even in hypothermia, reversal with sugammadex
was complete although hypothermia patients required
additional 46 s to recover compared with the normothermia
patients.
Studies have reported that cardiac output declined
markedly in response to hypothermia [19,20]. The onset
of action of sugammadex may be affected by the cardiac
output and muscle blood flow. The reduction of cardiac
output is linearly associated with hypothermia, which is
associated with decreased regional blood flow distribution
compared with that of normothermia [19]. A lower






























Figure 2 Mean values (SD) for mean arterial pressure and heart rate f
rocuronium-induced neuromuscular block. *p < 0.001 compared with vais reduced, which leads to a slower transfer rate of
sugammadex and a slower reduction of free (unbound)
rocuronium in the plasma. Although we could not measure
the the pharmacokinetics of rocuronium and sugammadex,
we suspect that this effect may reduce the speed of the
recovery from NMB by sugammadex during hypothermia.
Good and optimal surgical conditions (99%) during
deep NMB (good 32% and optimal 67%) were achieved
with a higher frequency than during moderate NMB
(82%) (good 48% and optimal 34%) in retroperitoneal
laparoscopies [8]. In the present study, a PTC 1–2 in deep
NMB is maintained during anesthesia with continuous
infusion of rocuronium, which can achieve total dia-
phragmatic paralysis in response to tracheal suction
[21]. We suspect that the ability to provide deep
NMB throughout the procedure may enable improved
surgical access and an enhanced visual field.
In adults, the infusion rate of rocuronium to maintain
10% of first twitch of TOF was 0.3 - 0.4 mg.kg−1 h−1
under inhalational anesthesia [22]. In the present study,
rocuronium requirements for steady block PTC 1 – 2 in
long duration (about 3 hours) were 113.2 ± 31.1 mg
(0.6 mg.kg−1 h−1) in hypothermia and 115.8 ± 40.7 mg
(0.7 mg.kg−1 h−1) in normothermia, which indicates that
the requirement of rocuronium with continuous infusionmin after injection























or 3 minutes (min) in patients receiving sugammadex in deep
lues before sugammadex was injected.
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normothermia (Table 1).
Greater degrees of change and heart rate fluctuations
at 2 – 10 min were demonstrated after reversal with
neostigmine–glycopyrrolate, compared with sugammadex
[23]. In this study, there was a decrease in heart rate
during 3 min after sugammadex reversal in both groups
(Figure 2). The heart rate stability after sugammadex
administration may allow hemodynamic stability and
minimal cardiovascular adverse effects. The overall
prevalence of adverse events after sugammadex was
similar to placebo and neostigmine study groups [24]. Our
study did not identify any PONV or other adverse effects
following administration of sugammadex.
A peripheral skin temperature below 32°C with
sustained and normal body temperature is associated
with changes in both twitch tension and TOF ratio that
may be a source of error when evaluating neuromuscular
function [25]. The time course of action of NMB agents
is prolonged by more than 50% in a cooled arm (skin
temperature < 32°C) compared with a normothermic
arm, which is especially unreliable in the PTC method
[26]. So, the skin temperature over the monitored
arm was more than 32°C which was maintained by
wrapping the arm in cotton wool and forced-air
warming in both groups in this study.
After the reversal of NMB by sugammadex, full
recovery of the TOF ratio is possible when first
twitch is still depressed. The TOF ratio as the only
measurement for the adequate reversal of NMB by
sugammadex may not always be reliable [27]. Although
measurement of the TOF ratio is considered the standard
in the present study, twitch height also has to be taken
into account in the further study. The limitations of
the current trial were no measurement of the plasma
concentration of rocuronium, no evaluation of the twitch
tension after the administration of sugammadex, and the
limited sample size.Conclusions
Sugammadex can completely restore NMB from deep
rocuronium-induced NMB in hypothermia. An additional
46 s was required for the time to TOF ratio 0.9 from a
deep NMB in hypothermia patients. However, we propose
that this prolonged recovery time is clinically acceptable.
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